

Luxembourg, 6 November 2024

PRESS RELEASE

Luxempart agrees to tender its shares in Nexus AG, a leading European healthcare software provider, into the public takeover offer to be launched by TA Associates

On November 5, 2024, Nexus AG announced that it has entered into an investment agreement with a holding company controlled by investment funds advised and managed by affiliates of TA Associates Management, L.P. (together "TA") with the purpose to enter into a strategic partnership supporting the long-term growth of Nexus AG. In this context, TA has announced their intention to launch a voluntary public takeover offer. This refers to all outstanding shares at an offerprice of € 70.0 per share in cash.

Luxempart has signed an irrevocable agreement to tender all its shares into this offer, which remains subject to a minimum acceptance threshold of 50% plus one share and customary regulatory conditions. With a stake of more than 10%, Luxempart has been an anchor shareholder of Nexus AG for several years and now expresses its support to this takeover offer.

This transaction represents an important milestone in Luxempart's ongoing commitment to fostering growth and value in innovative companies. TA's acquisition of Luxempart's stake in Nexus reflects a mutual confidence in Nexus' robust market position and its continued growth potential in the health technology sector. Since investing in Nexus in 2022, Luxempart has supported the company through a period of strategic growth, contributing to the expansion of its product offerings and market footprint in Europe. With TA's deep expertise in supporting technology-driven businesses, Nexus is well-positioned to leverage this new partnership for future advancements in healthcare solutions under the private ownership by TA following the envisaged delisting.

In case of a successful tender offer, proceeds for Luxempart would amount to ca. € 123m, which would represent a positive impact of ca. €27m on Luxempart's Net Asset Value as of June 30, 2024.

For more information on the announcement: <https://www.nexus-ehealth.com/company/news>

About Nexus

With annual group revenue of more than EUR 240 million and c. 2,030 employees, Nexus is one of the leading healthcare software companies in Europe, offering hospital information systems (HIS) and diagnostics software (DIS). Founded in 1989 and headquartered in Donaueschingen, Germany, Nexus is serving over 10,000 customers across 71 countries. Customer groups include hospitals, rehabilitation centres and nursing homes. Approximately 65% of Nexus FY23 revenue is recurring due to its high share of maintenance business. Germany accounts for 55% of revenue, Switzerland 21%, the Netherlands 11%, and Poland 5%.

LUXEMPART S.A.

Siège social : 12, rue Léon Laval | L-3372 Leudelange | Luxembourg | T +352 437 435 101 | www.luxempart.lu | luxempart@luxempart.lu
RCS Luxembourg : B27846



About Luxempart

Luxempart is a Luxembourg-based listed investment company with a net worth of EUR 2.3bn backed by Luxembourgish entrepreneurial families. With permanent capital and a professional investment team, Luxempart provides flexible long-term financing solutions to entrepreneurs, families and management and actively supports its portfolio companies in their growth and international expansion. Luxempart's Direct Investment strategy consists in investing equity tickets ranging from EUR 25m up to EUR 100m in the DACH region, France, BeLux and Northern Italy.

Contact: John Penning +352 437 43 5117

www.luxempart.lu

LUXEMPART S.A.

Siège social : 12, rue Léon Laval | L-3372 Leudelange | Luxembourg | T +352 437 435 101 | www.luxempart.lu | luxempart@luxempart.lu
RCS Luxembourg : B27846